News | Oncology Diagnostics | August 24, 2016

Guided Therapeutics Sells First LuViva Advanced Cervical Scan to Russia

65 million Russian women at risk of developing cervical cancer

Guided Therapeutics, LuViva Advanced Cerivcal Scan, first to Russia, cervical cancer

August 24, 2016 — Guided Therapeutics Inc. announced in late July that it has sold the first LuViva Advanced Cervical Scan to its distributor in Russia.

The LuViva will be used for marketing clinical studies and for testing as part of the approval process by the Russian Federal Service for Control over Healthcare and Social Development, more commonly known as "Roszdravnadzor." Approval is expected in 2017.

Cervical cancer is the second most diagnosed cancer among Russian women ages 15 to 44 years, with the highest cancer mortality rate, according to the 2016 ICO Information Centre on HPV and Cancer report fact sheet. There are 65.1 million women at risk of developing cervical cancer in Russia. Annually, 15,342 Russian women will be diagnosed with cervical cancer and 7,371 will die from the disease.

Worldwide, the market for cervical cancer screening and diagnostics, as currently practiced using cytology (Pap test) for primary screening, is estimated at $6 billion and is projected to grow to almost $9 billion by 2020. There are about 2.6 billion women aged 15 years and older who are at risk of developing cervical cancer worldwide.

LuViva is a diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of precancer that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which may result in eliminating costly, painful and unnecessary additional testing.

LuViva is intended for use with women who have undergone initial screening and are called back for follow up with a colposcopy examination, which in many cases, involves taking a biopsy of the cervix. It has also been used in clinical studies in Turkey and Nigeria as a means to screen women for cervical cancer where the availability of infrastructure necessary for Pap and HPV testing is restricted. The device is used in conjunction with the LuViva Cervical Guide single-use patient interface and calibration disposable.

For more information: www.guidedinc.com

Related Content

Novel Technique May Significantly Reduce Breast Biopsies
News | Breast Biopsy Systems | January 17, 2019
A novel technique that uses mammography to determine the biological tissue composition of a tumor could help reduce...
Digital Mammography Increases Breast Cancer Detection
News | Mammography | January 16, 2019
The shift from film to digital mammography increased the detection of breast cancer by 14 percent overall in the United...
Artificial Intelligence Used in Clinical Practice to Measure Breast Density
News | Artificial Intelligence | January 15, 2019
An artificial intelligence (AI) algorithm measures breast density at the level of an experienced mammographer,...
Videos | Interventional Radiology | January 11, 2019
Julius Chapiro, M.D., research faculty member and an...
Sponsored Content | Videos | Breast Imaging | January 11, 2019
Supplemental screening with ABUS helps personalize breast care for women with dense breasts and offers advanced...
AI Approach Outperformed Human Experts in Identifying Cervical Precancer
News | Digital Pathology | January 10, 2019
January 10, 2019 — A research team led by investigators from the National Institutes of Health and Global Good has de
Electronic Brachytherapy Effective in Long-Term Study of 1,000 Early-Stage Breast Cancers
News | Brachytherapy Systems, Women's Healthcare | January 07, 2019
Breast cancer recurrence rates of patients treated with intraoperative radiation therapy (IORT) using the Xoft Axxent...
Breast Cancer Patients Have Less Heart Damage With Heart Drug and Trastuzumab
News | Cardio-oncology | January 03, 2019
Breast cancer patients who take a heart drug at the same time as trastuzumab have less heart damage, according to a...
Heart Attack, Stroke Risks Increase Leading Up to Cancer Diagnosis
News | Cardio-oncology | December 21, 2018
Older adults with cancer are more likely to have had a heart attack or stroke in the months prior to their cancer...
Opto-Acoustic Imaging Helps Differentiate Breast Cancer Molecular Subtypes
News | Ultrasound Women's Health | December 20, 2018
Seno Medical Instruments Inc. (Seno Medical) reported results of a study demonstrating that morphologic and functional...